Innate Pharma Files 6-K, Reports Press Release
Ticker: IPHYF · Form: 6-K · Filed: Dec 11, 2025 · CIK: 1598599
| Field | Detail |
|---|---|
| Company | Innate Pharma SA (IPHYF) |
| Form Type | 6-K |
| Filed Date | Dec 11, 2025 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: filing, press-release, foreign-issuer
TL;DR
Innate Pharma dropped a 6-K on Dec 11, 2025, with a press release. Check it for updates.
AI Summary
Innate Pharma S.A. filed a Form 6-K on December 11, 2025, reporting a press release dated the same day. The filing indicates the company is a foreign private issuer and will file annual reports under Form 20-F. The principal executive office is located in Marseille, France.
Why It Matters
This filing provides an update from Innate Pharma, a biotechnology company, which could contain important information for investors regarding their operations or strategic developments.
Risk Assessment
Risk Level: low — This is a routine filing (Form 6-K) that primarily serves to report a press release and confirm filing status, rather than announcing significant financial events.
Key Players & Entities
- Innate Pharma S.A. (company) — Registrant
- December 11, 2025 (date) — Filing Date
- 001-39084 (other) — Commission File Number
- Marseille, France (location) — Principal Executive Office
- Form 20-F (document) — Annual Report Filing
- Exhibit 99.1 (document) — Press Release
FAQ
What is the purpose of this Form 6-K filing?
The Form 6-K filing on December 11, 2025, is to report a press release dated the same day and to indicate that Innate Pharma S.A. files annual reports under Form 20-F.
Where is Innate Pharma S.A. located?
Innate Pharma S.A.'s principal executive office is located at 117 Avenue de Luminy, BP 30191, 13009 Marseille, France.
What is the Commission File Number for Innate Pharma S.A.?
The Commission File Number for Innate Pharma S.A. is 001-39084.
Does Innate Pharma S.A. file annual reports under Form 20-F?
Yes, the filing indicates that Innate Pharma S.A. files annual reports under cover of Form 20-F.
What exhibit is included with this 6-K filing?
Exhibit 99.1, a Press Release dated December 11, 2025, is included with this 6-K filing.
Filing Stats: 158 words · 1 min read · ~1 pages · Grade level 9.8 · Accepted 2025-12-11 06:03:45
Filing Documents
- a6k-iphx251211.htm (6-K) — 8KB
- exhibit991-251211.htm (EX-99.1) — 14KB
- 0001628280-25-056412.txt ( ) — 23KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. INNATE PHARMA S.A. Date December 11, 2025 By s JONATHAN DICKINSON Name Jonathan Dickinson Title Chief Executive officer